These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21116263)

  • 41. Opioid receptors: drivers to addiction?
    Darcq E; Kieffer BL
    Nat Rev Neurosci; 2018 Aug; 19(8):499-514. PubMed ID: 29934561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.
    Robinson SE
    CNS Drug Rev; 2002; 8(4):377-90. PubMed ID: 12481193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crucial role of peripheral kappa-opioid receptors in a model of periodontal disease in rats.
    Pacheco CM; Queiroz-Junior CM; Maltos KL; Caliari MV; Pacheco DF; Duarte ID; Francischi JN
    J Periodontal Res; 2008 Dec; 43(6):730-6. PubMed ID: 18705652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Receptor-selective antagonism of opioid antinociception in female versus male rats.
    Craft RM; Tseng AH; McNiel DM; Furness MS; Rice KC
    Behav Pharmacol; 2001 Dec; 12(8):591-602. PubMed ID: 11856896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.
    Dalman FC; O'Malley KL
    J Neurosci; 1999 Jul; 19(14):5750-7. PubMed ID: 10407016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.
    Shahbazian A; Heinemann A; Schmidhammer H; Beubler E; Holzer-Petsche U; Holzer P
    Br J Pharmacol; 2002 Feb; 135(3):741-50. PubMed ID: 11834622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?
    Shippenberg TS
    Neuropsychopharmacology; 2009 Jan; 34(1):247. PubMed ID: 19079072
    [No Abstract]   [Full Text] [Related]  

  • 48. [Central kappa1-opioid receptors and arrhythmogenesis mechanism].
    Ugdyzhekova DS; Maslov LN; Lishmanov IuB
    Biull Eksp Biol Med; 1999 Jan; 127(1):57-9. PubMed ID: 10190006
    [No Abstract]   [Full Text] [Related]  

  • 49. Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.
    Obara I; Mika J; Schafer MK; Przewlocka B
    Br J Pharmacol; 2003 Oct; 140(3):538-46. PubMed ID: 12970097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
    Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
    Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comorbid pain and opioid addiction: psychosocial and pharmacological treatments.
    Wachholtz A; Ziedonis D; Gonzalez G
    Subst Use Misuse; 2011; 46(12):1536-52. PubMed ID: 21756033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. mu-Opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus.
    Tao R; Auerbach SB
    Brain Res; 2005 Jul; 1049(1):70-9. PubMed ID: 15935332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.
    Smith MA; Greene-Naples JL; Lyle MA; Iordanou JC; Felder JN
    J Pharmacol Exp Ther; 2009 Aug; 330(2):468-75. PubMed ID: 19403853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.
    Clark SD; Abi-Dargham A
    Biol Psychiatry; 2019 Oct; 86(7):502-511. PubMed ID: 31376930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical evidence of new opioid modulators for the treatment of addiction.
    Rodríguez-Arias M; Aguilar MA; Manzanedo C; Miñarro J
    Expert Opin Investig Drugs; 2010 Aug; 19(8):977-94. PubMed ID: 20629615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
    Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria.
    Raffa RB; Baron DA; Tallarida RJ
    Eur J Pharmacol; 2006 Jul; 540(1-3):200-1. PubMed ID: 16737694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockade effect of mu and kappa opioid antagonists on the anti-nociception induced by intra-periaqueductal grey injection of oxytocin in rats.
    Ge Y; Lundeberg T; Yu LC
    Brain Res; 2002 Feb; 927(2):204-7. PubMed ID: 11821014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.